Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of the invisaRED® IR REHAB Device When Used as an Adjunctive Therapy for Nociceptive Musculoskeletal Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The number of participants is projected to be thirty (30).~There will be an equitable distribution of male and female participants.~Women who are pregnant, trying to get pregnant, or nursing will be excluded from the study, as they should not receive Low-level Laser Therapy (LLLT). There is no evidence of harm to a an unborn baby however there have been no safety tests either, so for medical legal reasons we recommend never treating such individuals.~The participants will be 18 years or older.~The ethnicity of the participants will be equitably distributed.~Inclusion criteria will be individuals that may benefit from an adjunctive therapy for musculoskeletal pain.~Exclusion Criteria:~If you are pregnant, trying to get pregnant or nursing laser light therapy should be received only after the end of these conditions. There is no evidence of harm to a an unborn baby however there have been no safety tests either, so for medical legal reasons we recommend never treating areas directly over a developing child.~Individuals with hypertension, light sensitive epilepsy, cancer, heart disease, infectious skin disease, and severe varicose veins should not use this device.~People suffering from infectious and acute disease such as a fever should not use this device.~People who have hemorrhagic disease, vascular ruptures, skin inflammation, or any disease of the skin should not use this device.~Person with a history of lentigines, an autoimmune vascular disease that causes color changes in the legs or arms due to obstruction or stenosis of blood vessels.~A person with a history of erythema, an acquired, long-lasting reticulocyte red and pigmented rash, caused by persistent or repeated exposure to intense heat or infrared radiation.~Persons who are susceptible to or have a history of herpes in the treatment area~Anyone who has experienced problems subsequent to previous laser treatments~People who have immune system dysfunction such as Leukemia, Hemophilia, etc., and light sensitive persons should not use this device.~Use of laser light therapy in the ears, nose, eye, or throat is not recommended.~Individuals with a history of melanoma, raised moles, suspicious lesions, keloid scar formation, or healing problems should not undergo laser light therapy.~Individuals with active infections, open lesions, hives, herpetic lesions, cold sores, or tattoos and permanent make-up in the area of treatment should not undergo laser light therapy.~People who have used isotretinoin (commonly known as Accutane), tetracycline, St. John's Wort, or any photo sensitizing drugs in the last year should not undergo laser light therapy.~Individuals with autoimmune diseases such as Lupus, Scleroderma, or Vitiligo should not undergo laser light therapy.~Individuals who have pacemakers or other electro-stimulation devices surgically implanted should not undergo laser light therapy.~Any insulin dependent individual should consult their physician before undergoing laser light therapy.~All individuals considered vulnerable such as children, pregnant women, nursing home residents or other institutionalized persons, students, employees, fetuses, prisoners, and persons with decisional incapacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IR REHAB Device (Type: EXPERIMENTAL): Participants will receive 6 treatments of 15 minutes each with an active IR REHAB device over the period of three weeks.
- Sham Device (Type: SHAM_COMPARATOR): Participants will receive 6 treatments of 15 minutes each with a disabled (sham) IR REHAB device over the period of three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).